Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KRN 5500

Drug Profile

KRN 5500

Alternative Names: KRN5500; NSC-650426; SPK-241

Latest Information Update: 28 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kirin Brewery; Massachusetts General Hospital
  • Developer Fortovia Therapeutics
  • Class Cytostatic antibiotics; Non-opioid analgesics; Purine nucleosides
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuropathic pain; Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Neuropathic pain
  • No development reported Multiple myeloma
  • Discontinued Cancer

Most Recent Events

  • 13 Nov 2018 Midatech Pharma US has been acquired by Kanwa Holdings
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (IV)
  • 02 Nov 2015 KRN 5500 is still available for licensing in USA
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top